State drug price transparency reporting is becoming an ongoing compliance and operational responsibility for pharmaceutical manufacturers. As state requirements evolve, manual processes can make it difficult to identify reporting triggers, meet deadlines, and maintain consistent, accurate filings. 

State drug price transparency requirements vary by state, creating a complex reporting environment for pharmaceutical manufacturers. Different reporting triggers, deadlines, data requirements, and compliance obligations can make it difficult to maintain consistent processes across jurisdictions. As requirements continue to change, manufacturers need a repeatable way to identify obligations, coordinate the right data, and file accurately. 

In this on-demand webinar, Erica Petersohn explores how pharmaceutical manufacturers can move beyond reactive reporting and build a scalable approach to state drug price transparency. Learn how to address common reporting triggers, reduce compliance risk, centralize data, improve cross-functional coordination, and create reputable processes that can adapt as state requirements change.